JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib

Table 4

Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic (ROC) curve (AUC) of the presence of complete hematological response and early molecular response using cutoff values of baseline JAK2 levels (before imatinib treatment).

Variable	Cutoff	Sensitivity	Specificity	PPV	NPV	AUC (95% CI)	p-Value
Complete hematological response
JAK2 gene	≤0.90	0.63	0.62	0.77	0.44	0.61 (0.44–0.76)	0.30
Phosphorylated JAK2	≤0.58	0.59	0.85	0.89	0.50	0.78 (0.62–0.89)	<0.001
Total JAK2	≤370.79	0.93	0.54	0.81	0.78	0.80 (0.64–0.91)	<0.001
Early molecular response
JAK2 gene	≤0.80	0.63	0.63	0.71	0.53	0.58 (0.41–0.73)	0.45
Phosphorylated JAK2	≤0.70	0.75	0.81	0.85	0.69	0.82 (0.67–0.92)	<0.001
Total JAK2	≤187.48	0.83	0.75	0.84	0.75	0.87 (0.72–0.95)	<0.001